---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-059026"
form_type: "8-K"
ticker: "ADGM"
cik: "0002006986"
company_name: "Adagio Medical Holdings, Inc."
filed_at: "2026-05-12T12:05:25+00:00"
generated_at: "2026-05-12T12:17:15.505270+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Adagio Medical reports Q1 2026 net loss $7.0M, cash $12.9M; FULCRUM-VT shows 84% freedom from ICD shock

## Summary
- Net loss of $7.0M for Q1 2026 vs $7.7M in Q1 2025; no revenue; R&D expense $2.7M, SG&A $2.5M.
- Cash and equivalents of $12.9M as of March 31, 2026; up to $31M additional from milestone-based warrants.
- FULCRUM-VT pivotal trial: 84% freedom from ICD shock at 6 months, 2.4% MAE, 72% reduction in antiarrhythmic drug use.
- FDA approved IDE to expand FULCRUM-VT trial to evaluate next-generation vCLAS Ultra System.
- Successfully completed 13 cases under FDA Expanded Access in patients who failed prior ablation therapies.

## SEC filing metadata
- accession: 0001104659-26-059026
- form_type: 8-K
- ticker: ADGM
- cik: 0002006986
- company_name: Adagio Medical Holdings, Inc.
- filed_at: 2026-05-12T12:05:25+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2006986/000110465926059026/0001104659-26-059026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2006986/000110465926059026/tm2614299d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-059026
- JSON: https://secwatch.observer/filing/0001104659-26-059026.json
- Plain text: https://secwatch.observer/filing/0001104659-26-059026.txt

## Key facts
- Earnings Releases
  Adagio Medical Holdings, Inc. reported three months ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $7.0 million.
  - Period: three months ended March 31, 2026
  - Net income: Net loss for the three months ended March 31, 2026 was $7.0 million
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2026 was $7.0 million, compared to a net loss of $7.7 million for the three months ended March 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2006986/000110465926059026/0001104659-26-059026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.